Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma

International Journal of Surgery

Volumn 11, Issue 1, 2013, Pages 85-91

  Chen, Yu Ling ^a,b   Jeng, Yung Ming ^a,b   Hsu, Hey Chi ^a,b   Lai, Hong Shiee ^a,b   Lee, Po Huang ^a,b   Lai, Po Lin ^b   Yuan, Ray Hwang ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Early tumor recurrence; IMP3; Intrahepatic cholangiocarcinoma; Prognosis

Indexed keywords

CA 19-9 ANTIGEN; INSULIN LIKE GROWTH FACTOR II MRNA BINDING PROTEIN 3; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CHOLANGIOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; RNA-BINDING PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872599685     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2012.11.021     Document Type: Article

References (44)

1. Lazaridis K.N., Gores G.J. Cholangiocarcinoma. Gastroenterology 2005, 128(6):1655-1667. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40(3):472-7.
2. Endo I., Gonen M., Yopp A.C., Dalal K.M., Zhou Q., Klimstra D., et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008, 248(1):84-96.
3. Kawarada Y., Yamagiwa K., Das B.C. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg 2002, 183(6):679-685.
4. Yamamoto M., Ariizumi S. Surgical outcomes of intrahepatic cholangiocarcinoma. Surg Today 2011, 41(7):896-902.
5. Fu X.H., Tang Z.H., Zong M., Yang G.S., Yao X.P., Wu M.C. Clinicopathologic features, diagnosis and surgical treatment of intrahepatic cholangiocarcinoma in 104 patients. Hepatobiliary Pancreat Dis Int 2004, 3(2):279-283. Suzuki S, Sakaguchi T, Yokoi Y, Okamoto K, Kurachi K, Tsuchiya Y, et al. Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg 2002;26(6):687-93.
6. Wang T., Fan L., Watanabe Y., McNeill P.D., Moulton G.G., Bangur C., et al. L523S, an RNA binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003, 88(6):887-894.
7. Yantiss R.K., Woda B.A., Fanger G.R., Kalos M., Whalen G.F., Tada H., et al. KOC (Komology Domain Containing Protein Overexpressed in Cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005, 29(2):188-195.
8. Mueller-Pillasch F., Pohl B., Wilda M., Lacher U., Beil M., Wallrapp C., et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999, 88(1):95-99.
9. Monk D., Bentley L., Beechey C., Hitchins M., Peters J., Preece M.A., et al. Characterisation of the growth regulating gene IMP3, a candidate for Silver-Russell syndrome. J Med Genet 2002, 39(8):575-581.
10. Jeng Y.M., Wang T.H., Lu S.H., Yuan R.H., Hsu H.C. Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br J Surg 2009, 96(1):66-73.
11. Zhao H., Mandich D., Cartun R.W., Ligato S. Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn Cytopathol 2007, 35(11):700-704.
12. Findeis-Hosey J.J., Yang Q., Spaulding B.O., Wang H.L., Xu H. IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol 2010, 41(4):477-484. Findeis-Hosey JJ, Xu H. Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer. Biotech Histochem 2012;87(1):24-9.
13. Lu D., Vohra P., Chu P.G., Woda B., Rock K.L., Jiang Z. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol 2009, 33(4):521-525.
14. Walter O., Prasad M., Lu S., Quinlan R.M., Edmiston K.L., Khan A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol 2009, 40(11):1528-1533.
15. Do S.I., Kim Y.W., Park H.R., Park Y.K. Expression of insulin-like growth factor-II mRNA binding protein 3 (IMP3) in osteosarcoma. Oncol Res 2008, 17(6):269-272.
16. Hoffmann N.E., Sheinin Y., Lohse C.M., Parker A.S., Leibovich B.C., Jiang Z., et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008, 112(7):1471-1479.
17. Köbel M., Xu H., Bourne P.A., Spaulding B.O., Shih I., Mao T.L., et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol 2009, 22(3):469-475.
18. Zheng W., Yi X., Fadare O., Liang S.X., Martel M., Schwartz P.E., et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 2008, 32(2):304-315.
19. Sitnikova L., Mendese G., Liu Q., Woda B.A., Lu D., Dresser K., et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 2008, 14(6):1701-1706.
20. Yuan R.H., Wang C.C., Chou C.C., Chang K.J., Lee P.H., Jeng Y.M. Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol 2009, 16(6):1711-1719.
21. Jeng Y.M., Chang C.C., Hu F.C., Chou H.Y.E., Kao H.L., Wang T.H., et al. Expression of RNA-binding protein IMP-3 promotes tumor invasion and predicts high tumor stage, early tumor recurrence, and poor prognosis in hepatocellular carcinoma. Hepatology 2008, 48(4):1118-1127.
22. Chen S.T., Jeng Y.M., Chang C.C., Chang H.H., Huang M.C., Juan H.F., et al. Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma. Cancer Sci 2011, 102(12):2191-2198.
23. Kim K.Y., Li S., Cha J.D., Zhang X., Cha I.H. Significance of molecular markers in survival prediction of oral squamous cell carcinoma. Head Neck 2012, 34(7):929-936.
24. Riener M.O., Fritzsche F.R., Clavien P.A., Pestalozzi B.C., Probst-Hensch N., Jochum W., et al. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Hum Pathol 2009, 40(10):1377-1383.
25. Sobin L.H., Wittekind C. TNM classification of malignant tumours 2002, Wiley-Liss, New York, Chichester. 6th ed. L.H. Sobin, W. Ch (Eds.).
26. Tonouchi A., Ohtsuka M., Ito H., Kimura F., Shimizu H., Kato M., et al. Relationship between pancreatic secretory trypsin inhibitor and early recurrence of intrahepatic cholangiocarcinoma following surgical resection. Am J Gastroenterol 2006, 101(7):1601-1610.
27. Nakagohri T., Kinoshita T., Konishi M. Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World J Surg 2008, 32(2):2675-2680.
28. Nuzzo G., Giuliante F., Ardito F., De Rose A.M., Vellone M., Clemente G., et al. Intrahepatic cholangiocarcinoma: prognostic factors after liver resection. Updates Surg 2010, 62(1):11-19.
29. de Jong M.C., Nathan H., Sotiropoulos G.C., Paul A., Alexandrescu S., Marques H., et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011, 29(23):3140-3145.
30. Saxena A., Chua T.C., Sarkar A., Chu F., Morris D.L. Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit. J Gastrointest Surg 2010, 14(7):1128-1138.
31. Chen L.P., Li C., Wang C., Wen T.F., Yan L.N., Li B. Predictive factors of recurrence for patients with intrahepatic cholangiocarcinoma after hepatectomy. Hepatogastroenterology 2012, 59(118):1765-1768.
32. Zhou J.X., Li Y., Chen S.X., Deng A.M. Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma. J Exp Clin Cancer Res 2011 Jan 6, [Epub ahead of print]. 10.1186/1756-9966-30-2.
33. Yonglitthipagon P., Pairojkul C., Chamgramol Y., Loukas A., Mulvenna J., Bethony J., et al. Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma. Hum Pathol 2012, 43(10):1719-1730.
34. Hirashita T., Iwashita Y., Ohta M., Komori Y., Eguchi H., Yada K., et al. Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma. J Gastrointest Surg 2012, 16(4):842-848.
35. Nielsen J., Christiansen J., Lykke-Andersen J., Johnsen A.H., Wewer U.M., Nielsen F.C. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999, 19(2):1262-1270.
36. Findeis-Hosey J.J., Xu H. The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol 2011, 42(3):303-314. Hart J, Parab M, Mandich D, Cartun RW, Ligato S. IMP3 immunocytochemical staining increases sensitivity in the routine cytologic evaluation of biliary brush specimens. Diagn Cytopathol 2012;40(4):321-6.
37. Ligato S., Zhao H., Mandich D., Cartun R.W. KOC (K homology domain containing protein overexpressed in cancer) and S100A4-protein immunoreactivity improves the diagnostic sensitivity of biliary brushing cytology for diagnosing pancreaticobiliary malignancies. Diagn Cytopathol 2008, 36(8):561-567.
38. Levy M., Lin F., Xu H., Dhall D., Spaulding B.O., Wang H.L. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol 2010, 41(9):1210-1219.
39. Vikesaa J., Hansen T.V., Jonson L., Borup R., Wewer U.M., Christiansen J., et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006, 25(7):1456-1468.
40. Yaniv K., Fainsod A., Kalcheim C., Yisraeli J.K. The RNA-binding protein Vg1 RBP is required for cell migration during early neural development. Development 2003, 130(23):5649-5661.
41. Samanta S., Sharma V.M., Khan A., Mercurio A.M. Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer. Oncogene 2012, 31(44):4689-4697.
42. Jiang Z., Chu P., Woda B.A., Rock K.L., Liu Q., Hsieh C.C., et al. Analysis of RNA binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006, 7(7):556-564.
43. Cho S.Y., Park S.J., Kim S.H., Han S.S., Kim Y.K., Lee K.W., et al. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol 2010, 17(7):1823-1830.
44. Shen W.F., Zhong W., Liu Q., Sui C.J., Huang Y.Q., Yang J.M. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg 2011, 35(9):2083-2091.